SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has traders focused on Starknets privacy and Bitcoin DeFi plans, alongside its STARK-based post-quantum security narrative. Bullish momentum and ecosystem optimism are tempered by concerns about token unlocks, selling pressure, and whether the move is a short-lived pump.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a recent price rebound, with traders debating whether the move can continue or give way to another pullback. Bulls point to Bittensors decentralized-AI ecosystem and subnet development, while cautious voices question adoption and near-term catalysts amid broader crypto and macro uncertainty.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being tied to a weak housing markethigh mortgage rates and affordability pressures are weighing on transactionswith lowered guidance adding to concerns despite revenue growth. Bearish traders see further downside, while bulls argue the shares are oversold and point to growth in rentals, mortgages and AI-enabled products.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Attention centers on Compounds institutional-market push, including a reported launch, new leadership and investment plans, alongside anticipation for V4. Many traders are bullish on COMPs limited supply and potential breakout, while skeptics point to weak relative price action and concerns about protocol liquidity.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is drawing attention after a recent rise in trading activity, with traders comparing the companys Niemann-Pick franchise to IntraBios reported acquisition and arguing that Zevra may be undervalued; some speculate about a potential buyer, but no deal is confirmed. The discussion also points to the pending European re-examination and upcoming results, with views divided over regulatory prospects and the stocks gains.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual trading powered by Hyperliquid, with traders also highlighting the tokens AI-agent and cross-chain Intents narrative. The reaction is largely bullish, though some remain cautious about pullbacks and the earlier NEAR Intents exploit.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

A Brazilian federal appeals court restored Sigma Lithiums existing mining licenses, allowing operations to resume after a shutdown. Traders welcomed the restart, while noting that the plant expansion remains blocked pending a community-related survey, leaving legal and execution risks in focus.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Cathie Woods latest portfolio reshuffle, including ARKK trims to AMD, SpaceX and Alphabet alongside biotech buying elsewhere in ARKs funds, is prompting debate over her trade timing and track record; some traders are also pointing to ARKKs recent strength and breakout attempts.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and consolidation are driving IBIT discussion, with many traders treating pullbacks as buying opportunities and anticipating further gains, while others warn that momentum could fade. The conversation is largely about Bitcoins direction rather than a confirmed IBIT-specific catalyst.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are drawing attention as traders assess whether GDXs correction is bottoming, with higher real yields and a stronger dollar cited as near-term pressure on gold and miners. Some see signs of a rebound and are buying dips, while others want confirmation and warn that the pullback may continue; longer-term bulls point to central-bank buying and concerns about debt and currency debasement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Equity

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) delivered earnings and revenue surprises of +16.67% and +205.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MediciNova (MNOV) Expected to Announce Quarterly Earnings on Wednesday

MediciNova (NASDAQ:MNOV) will be releasing earnings after the market closes on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-medicinova-inc-stock...

D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV)

D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of MediciNova in a report on Monday...

MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest

MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 168,023 shares, a decline of 16.4% from the March...

MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm...

MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average   - Here's Why

MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average - Should You Sell...

MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Here's What Happened

MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell...

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Medicinova Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.52
Prev Close	$1.54
Open	$1.54
Dividend Yield	0.00%
50-Day Moving Average	$1.76
Beta	0.51
Avg. Volume	866,551.98
PE Ratio	-6.95

52-Week High	$3.90
52-Week Low	$1.17
Market Capitalization	$74.82M
EPS (Annual)	-$0.2445
Price to Book	2.01
Revenue Per Employee	$68,276.17

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNOV Fundamentals